Chiasma Reports Fourth Quarter and Year End 2018 Results
08 mars 2019 16h05 HE
|
Chiasma, Inc.
On track for top-line data from Phase 3 CHIASMA OPTIMAL trial of octreotide capsules, conditionally trade-named MYCAPSSA®, expected in Q3 2019 Assuming positive OPTIMAL data, NDA submission expected...
Chiasma to Participate in Three Investor Conferences in March
04 mars 2019 16h05 HE
|
Chiasma, Inc.
WALTHAM, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces Support for Rare Disease Day 2019
28 févr. 2019 08h00 HE
|
Chiasma, Inc.
WALTHAM, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Previews Important Upcoming Milestones
03 janv. 2019 16h05 HE
|
Chiasma, Inc.
CHIASMA OPTIMAL Phase 3 topline data expected in Q3 2019 Company anticipates submitting U.S. NDA by year-end 2019, assuming positive CHIASMA OPTIMAL data, and if accepted for filing, further...
Chiasma Reports Third Quarter 2018 Results
08 nov. 2018 16h05 HE
|
Chiasma, Inc.
Topline Data from Phase 3 CHIASMA OPTIMAL Trial of Octreotide Capsules, Conditionally Trade-Named MYCAPSSA®, Anticipated by September 2019 Company randomizes 80th patient in Phase 3 MPOWERED™...
Chiasma Supports Acromegaly Awareness Day
01 nov. 2018 08h00 HE
|
Chiasma, Inc.
Company continues to advance its novel octreotide capsules candidate through Phase 3 clinical trials in the U.S. and E.U. WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:...
Chiasma Announces Oral Presentation at the 18th Congress of the European Neuroendocrine Association
17 oct. 2018 16h05 HE
|
Chiasma, Inc.
Presentation by Dr. Maria Fleseriu, a widely-published endocrinologist and recognized thought leader in the field of acromegaly WALTHAM, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc....
Chiasma Completes Enrollment of CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly
01 oct. 2018 16h01 HE
|
Chiasma, Inc.
Topline data now expected in September 2019, versus prior guidance of 4Q 2019 WALTHAM, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical...
Chiasma Announces Poster Presentation at the 9th International Congress of the Growth Hormone Research and IGF Societies
13 sept. 2018 16h01 HE
|
Chiasma, Inc.
Among the initial findings, some acromegaly patients managed by injectable somatostatin receptor ligands (SRLs) report symptoms that may interfere with daily life Treatment burden associated with...
Chiasma to Present at the H.C. Wainwright 20th Annual Global Investment Conference
29 août 2018 16h05 HE
|
Chiasma, Inc.
NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...